Immune-related adverse events (irAEs) are a range of complications associated with the use
of immune-checkpoint inhibitors (ICIs). Two major classes of ICIs widely used are Cytotoxic …

Simple Summary Immune-checkpoint inhibitors (ICIs) are increasingly used in the treatment
of cancer, but they cause immune-related adverse events (irAEs) in around 40% of patients …

Cancer remains a leading cause of mortality on a global scale. Lung cancer, specifically non–
small cell lung cancer (NSCLC), is a prominent contributor to this burden. The management …

Purpose: Genetic differences in immunity may contribute to toxicity and outcomes with
immune checkpoint inhibitor (CPI) therapy, but these relationships are poorly understood …

Background Immune-related adverse events (irAE) induced by immune checkpoint inhibitors
(ICI) are a treatment-limiting barrier. There are few large-scale studies that estimate irAE …

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced
malignancies, including non-small cell lung cancer (NSCLC). These agents have improved …

Over the past few decades, immune checkpoint inhibitors (ICIs) have emerged as promising
therapeutic options for the treatment of various cancers. These novel treatments effectively …

Immune checkpoint inhibitor (ICI) therapy has revolutionised the treatment of various cancer
types. ICIs reinstate T-cell function to elicit an anti-cancer immune response. The resulting …

Immunotherapy, including immune checkpoint inhibitor (ICI) therapy, has been a paradigm
shift in cancer therapeutics, producing durable cancer responses across a range of primary …

Abstract Background PD-1/PD-L1 inhibitors have brought remarkable benefits but can cause
profound immune-related adverse events (irAEs). The host immunogenetic background is …